Kaken Pharmaceutical signs agreement with Dong-A ST for Clenafin/Jublia in Korea
Tuesday, May 31, 2016
Kaken Pharmaceutical Co Ltd :
Says Kaken Pharmaceutical and A Korea-based firm Dong-A ST Co Ltd concluded an exclusive distribution agreement for the topical formulation for Onychomycosis "Clenafin / Jublia" in Korea.
Says according to the agreement, Kaken hereby grant to Dong-A the exclusive right for development and sales of the Product in Korea.
Source : reuters.com
